1. Home
  2. INTG vs RLYB Comparison

INTG vs RLYB Comparison

Compare INTG & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intergroup Corporation (The)

INTG

Intergroup Corporation (The)

HOLD

Current Price

$35.17

Market Cap

87.0M

Sector

Real Estate

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.69

Market Cap

86.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTG
RLYB
Founded
1965
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.0M
86.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
INTG
RLYB
Price
$35.17
$16.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
111.2K
25.5K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.67
6.16
Revenue
$74,753,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$52.49
$2.75
Revenue Growth
4.43
43.00
52 Week Low
$12.25
$0.48
52 Week High
$52.00
$17.57

Technical Indicators

Market Signals
Indicator
INTG
RLYB
Relative Strength Index (RSI) 53.81 63.58
Support Level $31.59 $15.68
Resistance Level $38.27 $17.09
Average True Range (ATR) 2.89 0.42
MACD 0.85 0.05
Stochastic Oscillator 81.77 66.67

Price Performance

Historical Comparison
INTG
RLYB

About INTG Intergroup Corporation (The)

The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: